Related Experiment Video

Updated: Jun 5, 2025

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.4K

Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continues

Justin H Berger1, Brian N Finck2

  • 1Division of Pediatric Cardiology, Department of Pediatrics and.

The Journal of Clinical Investigation
|December 16, 2024
PubMed

Insights

Sodium glucose cotransporter 2 inhibitors (SGLT2i) show clinical benefits for heart failure, but their exact cardiovascular mechanisms remain unclear. New research suggests SGLT2i effects differ from exogenous ketones, indicating complex, multifaceted actions.

Area of Science:

  • Cardiology
  • Metabolic Research
  • Pharmacology

Background:

  • Sodium glucose cotransporter 2 inhibitors (SGLT2i) are widely used for heart failure treatment.
  • The precise cardiovascular mechanisms underlying SGLT2i benefits are not fully understood.
  • Enhanced ketogenesis is a proposed, but not fully established, mechanism.

Purpose of the Study:

  • To investigate the cardiovascular mechanisms of action for SGLT2 inhibitors.
  • To compare the metabolic effects of SGLT2 inhibitors with exogenous ketone administration.
  • To elucidate the role of ketogenesis in SGLT2 inhibitor therapy.

Main Methods:

  • Metabolic flux studies were conducted.
  • The effects of SGLT2 inhibitors were compared directly with exogenous ketone administration.
  • Differential metabolic effects were analyzed.

Main Results:

  • SGLT2 inhibitors and exogenous ketones demonstrated distinct metabolic effects.
  • The study provides evidence against a sole mechanism of action via enhanced ketogenesis.
  • Metabolic flux analysis revealed nuanced differences between the interventions.

Conclusions:

  • The cardiovascular mechanisms of SGLT2 inhibitors are likely pleiotropic, involving multiple pathways.
  • Further research is required to fully comprehend the beneficial effects of SGLT2 inhibitors in heart failure.
  • Ketogenesis may not be the primary driver of SGLT2 inhibitor efficacy.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.5K

Related Concept Videos

Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.3K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297